Adrenocortical carcinoma (ACC) · line 1 · EDP-M (etoposide + doxorubicin + cisplatin + mitotane) — FIRM-ACT regimen
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-EDP-M-ACC |
| ID | IND-ACC-1L-MITOTANE-EDP |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-ADRENOCORTICAL-CARCINOMA |
| Sources | SRC-ENSAT-ACC-2018 SRC-ESMO-ACC-2020 SRC-FIRM-ACT-FASSNACHT-2012 SRC-NCCN-NET-2025 |
Notes
STUB pending clinical co-lead sign-off (CHARTER §6.1). FIRM-ACT trial figures (ORR, PFS, OS, regimen doses/schedule) verified via PubMed and secondary trial-summary sources during this authoring pass (PMID 22551107, NCT00094497) — cross-check against the primary NEJM 2012 publication before treating this Indication as clinically authoritative.
Used By
Algorithms
ALGO-ACC-1L- ALGO-ACC-1L